Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations

Abstract

The Middle East and Africa (MEA) region, a large geographical area, lies at the confluence of Asian, Caucasian and African races and comprises of a population with several distinct ethnicities. The course of management of non-small cell lung cancer (NSCLC) differs as per patients’ performance status as well as stage of disease, requiring personalized therapy decisions. Although management of NSCLC has received a significant impetus in the form of molecularly targeted therapies and immune therapies in last few years, surgery remains gold standard for patients with early-stage disease. In case of unresectable disease, radiotherapy and chemotherapy are the primary management modalities. With newer therapies being approved for treatment of early stage disease, use of multi-disciplinary team (MDT) for comprehensive management of NSCLC is of prime importance. A group of experts with interest in thoracic oncology, deliberated and arrived at a consensus statement for the community oncologists treating patients with NSCLC in the MEA region. The deliberation was based on the review of the published evidence including literature and global and local guidelines, subject expertise of the participating panellists and experience in real-life management of patients with NSCLC. We present the proposed regional adaptations of international guidelines and recommends the MDT approach for management of NSCLC in MEA. © 2021

Description

Keywords

Immunotherapy, Middle east and africa region, Multi-disciplinary team, Non-small cell lung cancer, Radiotherapy, Surgery, Targeted therapy, Africa, Carcinoma, non-small-cell lung, Humans, Lung neoplasms, Middle east, Oncologists, Anaplastic lymphoma kinase, Bevacizumab, Cetuximab, Circulating tumor dna, Cisplatin, Docetaxel, Durvalumab, Epidermal growth factor receptor, Epidermal growth factor receptor kinase inhibitor, Erlotinib, Fluorodeoxyglucose f 18, Gefitinib, Gemcitabine, Nivolumab, Osimertinib, Pazopanib, Vinorelbine tartrate, Apoptosis, Bronchoscopy, Cancer immunotherapy, Cancer mortality, Cancer radiotherapy, Cancer staging, Cancer therapy, Computer assisted tomography, Consensus, Disease free survival, Endoscopic ultrasonography, Fine needle aspiration biopsy, Fluorescence in situ hybridization, Genotype, Histology, Hospitalization, Human, Immunohistochemistry, Induction chemotherapy, Liquid biopsy, Lymph node dissection, Mediastinum lymph node, Molecularly targeted therapy, Multidisciplinary team, Non small cell lung cancer, Nonhuman, Nuclear magnetic resonance imaging, Overall survival, Palliative therapy, Personalized medicine, Practice guideline, Quality of life, Randomized controlled trial (topic), Review, Risk assessment, Risk factor, Stereotactic body radiation therapy, Tumor volume, Video assisted thoracoscopic surgery, Lung tumor, Oncologist

Citation

Endorsement

Review

Supplemented By

Referenced By